Page 259 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 259
P0800 EFFECTIVENESS AND SAFETY OF COMBINATION NEW ePOSTERS
REGIMENS BASED SOFOSBUVIR WITH RIBAVIRIN,
P0801 DACLATASVIR OR SYMEPREVIR IN DIFFICULT PATIENTS
P0802 TO TREAT INFECTED WITH CHRONIC HEPATITIS C
P0803 Blaise Kutala*, Feryel Mourri, Nathalie Boyer, Veronique Sitruk,
P0804 Nathalie Giuily, Corinne Castelnau, Patrick Marcellin, Tarik Asselah,
France
P0805
ERADICATE HCV: TREATMENT AS PREVENTION IN
CHAOTIC DRUG USERS
Farsana Ahmad*, Linda Johnston, Brian Stephens, John Dillon,
The United Kingdom
SAFETY AND EFFICACY OF SOFOSBUVIR + SIMEPREVIR
WITHOUT RIBAVIRIN IN HEPATITIS C GENOTYPE
1-INFECTED PATIENTS WITH END-STAGE RENAL DISEASE
OR GFR <30ML/MIN
Hector E. Nazario*, Milka Ndungu, Apurva Modi, The United States
COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR
FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC
HEPATITIS C IN SCOTLAND
John Dillon*, Catrin Treharne, Ruth Howells, The United Kingdom
EFFICACY OF SOFOSBUVIR-BASED TREATMENT
REGIMENS IN HIV/HCV CO-INFECTED PATIENTS AFTER
LIVER TRANSPLANTATION: THE ANRS CO23 CUPILT STUDY
Teresa Maria Antonini*, Audrey Coilly, Sylvie Radenne,
Aurelie Veislinger, Danielle Botta-Fridlund, François Durand,
Pauline Houssel-Debry, Nassim Kamar, Valérie Canva, Philippe Perre,
Inga Bertucci, Jerome Dumortier, Vincent Leroy, Didier Samuel,
Georges-Philippe Pageaux, Jean-Charles Duclos-Vallee, France
ACHIEVEMENT OF SVR12 DESPITE THE PRESENCE OF
HCV VARIANTS RESISTANT TO FIRST GENERATION NS5A
INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS
AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION
WITH SOFOSBUVIR
Dharaben Patel,Yongsen Zhao, Joanne Fabrycki, Guangwei Yang,
Steven Podos, Hetal Kocinsk, Michael Mader, Ed Gane,
Christian Schwabe, David Apelian, Mingjun Huang, Wengang Yang*,
The United States
Vienna, Austria • April 22–26, 2015 259
REGIMENS BASED SOFOSBUVIR WITH RIBAVIRIN,
P0801 DACLATASVIR OR SYMEPREVIR IN DIFFICULT PATIENTS
P0802 TO TREAT INFECTED WITH CHRONIC HEPATITIS C
P0803 Blaise Kutala*, Feryel Mourri, Nathalie Boyer, Veronique Sitruk,
P0804 Nathalie Giuily, Corinne Castelnau, Patrick Marcellin, Tarik Asselah,
France
P0805
ERADICATE HCV: TREATMENT AS PREVENTION IN
CHAOTIC DRUG USERS
Farsana Ahmad*, Linda Johnston, Brian Stephens, John Dillon,
The United Kingdom
SAFETY AND EFFICACY OF SOFOSBUVIR + SIMEPREVIR
WITHOUT RIBAVIRIN IN HEPATITIS C GENOTYPE
1-INFECTED PATIENTS WITH END-STAGE RENAL DISEASE
OR GFR <30ML/MIN
Hector E. Nazario*, Milka Ndungu, Apurva Modi, The United States
COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR
FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC
HEPATITIS C IN SCOTLAND
John Dillon*, Catrin Treharne, Ruth Howells, The United Kingdom
EFFICACY OF SOFOSBUVIR-BASED TREATMENT
REGIMENS IN HIV/HCV CO-INFECTED PATIENTS AFTER
LIVER TRANSPLANTATION: THE ANRS CO23 CUPILT STUDY
Teresa Maria Antonini*, Audrey Coilly, Sylvie Radenne,
Aurelie Veislinger, Danielle Botta-Fridlund, François Durand,
Pauline Houssel-Debry, Nassim Kamar, Valérie Canva, Philippe Perre,
Inga Bertucci, Jerome Dumortier, Vincent Leroy, Didier Samuel,
Georges-Philippe Pageaux, Jean-Charles Duclos-Vallee, France
ACHIEVEMENT OF SVR12 DESPITE THE PRESENCE OF
HCV VARIANTS RESISTANT TO FIRST GENERATION NS5A
INHIBITORS IN GENOTYPE-1 HEPATITIS C PATIENTS
AFTER 8-WEEK THERAPY OF ACH-3102 IN COMBINATION
WITH SOFOSBUVIR
Dharaben Patel,Yongsen Zhao, Joanne Fabrycki, Guangwei Yang,
Steven Podos, Hetal Kocinsk, Michael Mader, Ed Gane,
Christian Schwabe, David Apelian, Mingjun Huang, Wengang Yang*,
The United States
Vienna, Austria • April 22–26, 2015 259
